{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:01:31Z","timestamp":1790740891018,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018036","name":"Nippon Shinyaku Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bone.2026.118056","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T16:15:23Z","timestamp":1787328923000},"page":"118056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Risk of bone fracture following saccharated ferric oxide in Japan"],"prefix":"10.1016","volume":"213","author":[{"given":"Kosuke","family":"Iwasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Terauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myles","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2026.118056_bb0005","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1572-0241.2008.01846.x","article-title":"Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease","volume":"103","author":"Gisbert","year":"2008","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bone.2026.118056_bb0010","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/ehf2.13265","article-title":"Iron deficiency in heart failure","volume":"8","author":"Loncar","year":"2021","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.bone.2026.118056_bb0015","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/01443615.2017.1363170","article-title":"Safety and efficacy of intravenous iron administration for uterine bleeding or postpartum anaemia: A narrative review","volume":"38","author":"Daniilidis","year":"2018","journal-title":"J. Obstet. Gynaecol."},{"key":"10.1016\/j.bone.2026.118056_bb0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/bja\/aeq361","article-title":"Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines","volume":"106","author":"Goodnough","year":"2011","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.bone.2026.118056_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2023.100677","article-title":"Iron-deficiency anemia in CKD: a narrative review for the kidney care team","volume":"5","author":"Hain","year":"2023","journal-title":"Kidney Med."},{"key":"10.1016\/j.bone.2026.118056_bb0030","first-page":"1639","article-title":"Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study","volume":"28","author":"Saint","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bone.2026.118056_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.bone.2026.118056_bb0040","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2025.06.006","article-title":"KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD)","volume":"109","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2026","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2026.118056_bb0045","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/anae.13773","article-title":"International consensus statement on the peri-operative management of anaemia and iron deficiency","volume":"72","author":"Mu\u00f1oz","year":"2017","journal-title":"Anaesthesia"},{"key":"10.1016\/j.bone.2026.118056_bb0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12882-017-0688-1","article-title":"Renal association clinical practice guideline on anaemia of chronic kidney disease","volume":"18","author":"Mikhail","year":"2017","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.bone.2026.118056_bb0055","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bone.2026.118056_bb0060","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1136\/gutjnl-2021-325210","article-title":"British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults","volume":"70","author":"Snook","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.bone.2026.118056_bb0065","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjh.16221","article-title":"UK guidelines on the management of iron deficiency in pregnancy","volume":"188","author":"Pavord","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bone.2026.118056_bb0070","first-page":"e895","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.bone.2026.118056_bb0075","author":"National Institute for Health and Care Excellence"},{"key":"10.1016\/j.bone.2026.118056_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/nu14142976","article-title":"Iron deficiency anemia: efficacy and limitations of nutritional and comprehensive mitigation strategies","volume":"14","author":"Kumar","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.bone.2026.118056_bb0085","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/ajh.27220","article-title":"Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions","volume":"99","author":"Van Doren","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bone.2026.118056_bb0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/17474086.2020.1709437","article-title":"Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia","volume":"13","author":"Pollock","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.bone.2026.118056_bb0095","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3324\/haematol.2014.111492","article-title":"Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management","volume":"99","author":"Rampton","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bone.2026.118056_bb0100","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1007\/s12325-023-02591-1","article-title":"Incidence of hypophosphatemia after intravenous administration of iron: a matching-adjusted indirect comparison of data from Japanese randomized controlled trials","volume":"40","author":"Fukumoto","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bone.2026.118056_bb0105","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2026.118056_bb0110","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study","volume":"94","author":"Schouten","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.118056_bb0115","author":"Nichi-iko Pharmaceutical Co Ltd"},{"key":"10.1016\/j.bone.2026.118056_bb0120","author":"Zeria Pharmaceutical Co Ltd"},{"key":"10.1016\/j.bone.2026.118056_bb0125","author":"American Regent Inc"},{"key":"10.1016\/j.bone.2026.118056_bb0130","author":"Sigma Company Ltd."},{"key":"10.1016\/j.bone.2026.118056_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118056_bb0140","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/14740338.2021.1912010","article-title":"Newer formulations of intravenous iron: A review of their chemistry and key safety aspects \u2013 hypersensitivity, hypophosphatemia, and cardiovascular safety","volume":"20","author":"Blumenstein","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bone.2026.118056_bb0145","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118056_bb0150","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","article-title":"Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia","volume":"45","author":"Shimizu","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.118056_bb0155","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.2169\/internalmedicine.51.7450","article-title":"Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide","volume":"51","author":"Yamamoto","year":"2012","journal-title":"Intern. Med."},{"key":"10.1016\/j.bone.2026.118056_bb0160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1258\/acb.2008.008151","article-title":"Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia","volume":"46","author":"Schouten","year":"2009","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.bone.2026.118056_bb0165","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","article-title":"Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease","volume":"23","author":"Wolf","year":"2014","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.bone.2026.118056_bb0170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.bone.2026.118056_bb0175","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12185-022-03401-0","article-title":"Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study","volume":"116","author":"Kawabata","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.bone.2026.118056_bb0180","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial","volume":"72","author":"Zoller","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.bone.2026.118056_bb0185","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside \u2013 a systematic review and meta-analysis","volume":"87","author":"Schaefer","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2026.118056_bb0190","article-title":"A case of hypophosphatemia and elevated intact fibroblast growth factor 23 levels after short-term saccharated ferric oxide administration in a young woman and database analysis of adverse drug reactions in Japan","volume":"21","author":"Kinoshita","year":"2024","journal-title":"Bone Rep."},{"key":"10.1016\/j.bone.2026.118056_bb0195","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/jbmr.4558","article-title":"Osteomalacia as a complication of intravenous iron infusion: A systematic review of case reports","volume":"37","author":"Vilaca","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118056_bb0200","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: An emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.bone.2026.118056_bb0205","article-title":"In-depth clinical characterization of intravenous iron infusion-induced hypophosphatemic osteomalacia and its resolution","volume":"9","author":"von Brackel","year":"2025","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2026.118056_bb0210","author":"Vifor Pharma UK Ltd"},{"key":"10.1016\/j.bone.2026.118056_bb0215","author":"Ministry of Health Labour and Welfare"},{"key":"10.1016\/j.bone.2026.118056_bb0220","author":"Ministry of Health Labour and Welfare"},{"key":"10.1016\/j.bone.2026.118056_bb0225","author":"CSL Behring Canada Inc"},{"key":"10.1016\/j.bone.2026.118056_bb0230","series-title":"Ferinject (ferric carboxymaltose) solution for injection - Australian Product Information","author":"Seqirus Pty Ltd","year":"2024"},{"key":"10.1016\/j.bone.2026.118056_bb0235","article-title":"A case of an insufficiency fracture of the medial proximal tibia secondary to osteomalacia associated with long-term saccharated ferric oxide administration","volume":"2017","author":"Ishimaru","year":"2017","journal-title":"Case Rep. Orthop."},{"key":"10.1016\/j.bone.2026.118056_bb0240","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1182\/blood.2025031806","article-title":"Ferric carboxymaltose increases fracture risk in patients and reduces bone formation in mice with iron deficiency anemia","volume":"148","author":"Wagner","year":"2026","journal-title":"Blood"},{"key":"10.1016\/j.bone.2026.118056_bb0245","first-page":"190","article-title":"Prevalence of noncommunicable dise ases in Japan using a newly developed administrative claims database covering young, middle-aged, and elderly people","volume":"5","author":"Okada","year":"2022","journal-title":"JMA J."},{"key":"10.1016\/j.bone.2026.118056_bb0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00198-019-05190-5","article-title":"The association between chronic kidney disease, falls, and fractures: a systematic review and meta-analysis","volume":"31","author":"Goto","year":"2020","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.118056_bb0255","first-page":"13","article-title":"Safety and efficacy of intravenous administration of iron preparations","volume":"74","author":"Grzywacz","year":"2017","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.bone.2026.118056_bb0260","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11154-024-09926-5","article-title":"No longer to be ignored: hypophosphatemia following intravenous iron administration","volume":"26","author":"Strubbe","year":"2024","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.bone.2026.118056_bb0265","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.arcped.2021.09.005","article-title":"X-linked hypophosphatemia: the medical expert\u2019s challenges and the patient\u2019s concerns on their journey with the disease","volume":"28","author":"Hamdy","year":"2021","journal-title":"Arch. Pediatr."},{"key":"10.1016\/j.bone.2026.118056_bb0270","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1507\/endocrj.45.431","article-title":"Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy","volume":"45","author":"Sato","year":"1998","journal-title":"Endocr. J."},{"key":"10.1016\/j.bone.2026.118056_bb0275","author":"Medicines and Healthcare Products Regulatory Agency (MHRA)"},{"key":"10.1016\/j.bone.2026.118056_bb0280","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1007\/s12325-021-01770-2","article-title":"Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome","volume":"38","author":"Glaspy","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.bone.2026.118056_bb0285","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1210\/clinem\/dgab852","article-title":"Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose","volume":"107","author":"Schaefer","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.118056_bb0290","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12882-023-03440-7","article-title":"The differential effect of modern intravenous iron on fibroblast growth factor 23 and phosphate in non-dialysis dependent CKD \u2013 the exploratory randomized controlled double-blind ExplorIRON-CKD study","volume":"25","author":"Kassianides","year":"2024","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.bone.2026.118056_bb0295","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/jbmr\/zjae021","article-title":"Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study","volume":"39","author":"Hsu","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.118056_bb0300","series-title":"StatPearls","article-title":"Anemia of Chronic Kidney Disease","author":"Hashmi","year":"2026"},{"key":"10.1016\/j.bone.2026.118056_bb0305","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.kint.2025.06.005","article-title":"Executive summary of the KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD)","volume":"109","author":"Babitt","year":"2026","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2026.118056_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/metabo15070460","article-title":"Fracture risk in chronic kidney disease: addressing an overlooked complication","volume":"15","author":"Gembillo","year":"2025","journal-title":"Metabolites"},{"key":"10.1016\/j.bone.2026.118056_bb0315","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","article-title":"Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents","volume":"26","author":"Bedimo","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.bone.2026.118056_bb0320","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/cix167","article-title":"Antiretrovirals, fractures, and osteonecrosis in a large international HIV cohort","volume":"64","author":"Borges","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bone.2026.118056_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166982","article-title":"Real-world assessment of renal and bone safety among patients with HIV infection exposed to tenofovir disoproxil fumarate-containing single-tablet regimens","volume":"11","author":"Nkhoma","year":"2016","journal-title":"PLoS One"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226002826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226002826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:40:17Z","timestamp":1790739617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328226002826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":65,"alternative-id":["S8756328226002826"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.118056","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of bone fracture following saccharated ferric oxide in Japan","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.118056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118056"}}